Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

Table 4 Univariate and Multivariable Logistical Regression Analysis of Risk Factors for Pazopanib-Induced Hypertension

	Univariate analysis		Multivariable analysis
	OR	P-value	OR	P-value
Age ≥ 60 years	0.81	0.767
Male (vs. female)	1.31	0.694
Baseline SBP ≥ 130 mmHg	5.32	0.058	4.62	0.197
Antihypertensive therapy at baseline
ACEIs or ARBs	4.88	0.044	4.31	0.075
Calcium channel blockers	3.5	0.160
Diuretics	2.17	0.400
Beta-blockers	0.5	0.348
≥ 2 Antihypertensives	4	0.078
Baseline CV Risk Factors
Diabetes	1.23	0.767
GFR < 60 ml/min/1.73m²	0.81	0.767
BMI > 30 kg/m²	0.76	0.694
Smoker^a	2.12	0.281
Oncologic Profile
Prior Nephrectomy	0.75	0.687
Pazopanib starting dose 800 mg	0.64	0.724

OR odds ratio, SBP systolic blood pressure, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CV cardiovascular, GFR glomerular filtration rate, BMI body mass index, ECOG Eastern Cooperative Oncology Group performance status
^aCurrent of past smoker

ISSN: 2057-3804